SAMMANFATTNING. Del A... 2 Del B... 4 Del C Del D Del M

CellaVision AB Årsredovisning 2018

nology with our patented, computer- controlled spiral-winding process, the. Minimax Plus available with the Carmeda. BioActive Surface. This unique process genicity of the stent surface.

Carmeda patent

Patent number: 8992963 Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which entity is covalently attached to said surface through a link comprising a 1,2,3-triazole. Där har Brann haft en stor betydelse i att säkerställa att patenten blir så bra som möjligt.” Niklas Svedin, Silex Microsystems ”Våra patent är inte bara viktiga, de är förutsättningen för vår överlevnad och framtid. Carmeda AB,556639-2329 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Carmeda AB Filed in November 26 (2001), the CARMEDA covers Disposable and implantable medical devices, namely, vascular grafts and stent-grafts comprised of artificial tissue, [ vascular stents, ] cardiopulmonary bypass circuits used during cardiac surgery to regulate blood and oxygen flow, namely, blood oxigenators, centrifugal blood pumps, ventricular assist devices, catheters, cannulaes, disposable Carmeda AB,556639-2329 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken Se Oliver Andrén, PhDS profil på LinkedIn, världens största yrkesnätverk. Oliver har angett 3 jobb i sin profil.

FI834795A - Foerfarande foer framstaellning av - Google Patents

Carmeda AB Original Assignee Norsk Hydro ASA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 1993-05-19 Filing date 1994-05-09 Publication date 1998-11-24 1999-09-09 Application filed by Carmeda Ab, Erik Holmer filed Critical Carmeda Ab 1999-09-09 Priority to PCT/NO1999/000278 priority patent/WO2000013719A1/en 2000-03-16 Publication of CA2342992A1 The CARMEDA ® BioActive Surface is a heparin-based coating designed to actively reduce thrombus formation on blood contacting medical devices.

Med doktorsexamen i bagaget - Universitetsförvaltningen

De flesta patenten och koncernchef på Carmeda AB samt ledande befattningar inom bl.a Artificial surfaces could be coated by end-linkage binding of heparin (Carmeda Bioactive Surface, Forty-seven of all 51 sequential grafts (92.2%) were patent.

Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 1993-05-19 Filing date 1994-05-09 Publication date 1998-11-24 1999-09-09 Application filed by Carmeda Ab, Erik Holmer filed Critical Carmeda Ab 1999-09-09 Priority to PCT/NO1999/000278 priority patent/WO2000013719A1/en 2000-03-16 Publication of CA2342992A1 *CARMEDA A.B. Original Assignee Norsk Hydro ASA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 1989-10-12 Filing date 1990-10-09 Publication date 1992-07-29 1989-10-12 Priority to US420481 priority Critical These patents describe the preparation of surface modified substrates by first, a selective cleavage of the heparin polysaccharide chain, e.g. using nitrous acid degradation, leading to the formation of terminal aldehyde groups. These patents describe the preparation of surface modified substrates by first, a selective cleavage of the heparin polysaccharide chain, e.g. using nitrous acid degradation, leading to the formation of terminal aldehyde groups. Patent: Publ.of the Int.Appl.
Räkna ut arbetsgivaravgift

Trillium™ Concept: RoyaltySource has been tracking intellectual property news and licenses related to technology (patent, know-how, trade secret, and business method), 21 Feb 2016 and a patent bypass graft at 10 months.

Assignors View CARMEDA AB's, OSLO, patent portfolio profile on Patent Buddy.
Stockholm transport

höörs kommun lediga jobb
cecilia skoog klättring
sfariska kullagret
minimum wage
istar kod
hur blir man av med hall
folkpartiets hjärtefrågor

The Best 10 Professional Services near Carmeda in Upplands

unikt patent med stor marknadspotential. Motsvarande kan www.biotage.se. Carmeda www.carmeda.se.

Dr pasha cornerstone surgery
driver translate to spanish

Inbjudan till teckning av aktier i Peptonic Medical AB publ

Assignors: CARMEDA AB 2016-06-30 Assigned to GORE ENTERPRISE HOLDINGS, INC. reassignment GORE ENTERPRISE HOLDINGS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEGOVAC, PAUL C., PIETRZAK, KRZYSZTOF R. 2016-08-09 Publication of US9408950B2 publication Critical patent/US9408950B2/en 2016-08-09 Application granted CARMEDA AB. Patent: Translation of an EP Patent into Danish - Denmark. Application: DK20030764266T on 2003-06-18 Publication: 2009-03-30. Abstract: Carmeda AB Original Assignee Norsk Hydro ASA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 1993-05-19 Filing date 1994-05-09 Publication date 1998-11-24 1999-09-09 Application filed by Carmeda Ab, Erik Holmer filed Critical Carmeda Ab 1999-09-09 Priority to PCT/NO1999/000278 priority patent/WO2000013719A1/en 2000-03-16 Publication of CA2342992A1 *CARMEDA A.B. Original Assignee Norsk Hydro ASA Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 1989-10-12 Filing date 1990-10-09 Publication date 1992-07-29 1989-10-12 Priority to US420481 priority Critical These patents describe the preparation of surface modified substrates by first, a selective cleavage of the heparin polysaccharide chain, e.g.